IN8bio, Inc. (INAB): Price and Financial Metrics


IN8bio, Inc. (INAB): $2.36

-0.04 (-1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INAB Stock Price Chart Interactive Chart >

Price chart for INAB

INAB Price/Volume Stats

Current price $2.36 52-week high $10.32
Prev. close $2.40 52-week low $2.00
Day low $2.24 Volume 11,200
Day high $2.40 Avg. volume 38,273
50-day MA $3.12 Dividend yield N/A
200-day MA $5.21 Market Cap 44.46M

IN8bio, Inc. (INAB) Company Bio


IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.


INAB Latest News Stream


Event/Time News Detail
Loading, please wait...

INAB Latest Social Stream


Loading social stream, please wait...

View Full INAB Social Stream

Latest INAB News From Around the Web

Below are the latest news stories about In8Bio Inc that investors may wish to consider to help them evaluate INAB as an investment opportunity.

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events: BIO CEO & Investor Conference, February 14 - 17, 2022Will Ho, Chief Executive Officer, will present a company overviewAvailable On-Demand February 14 - 17, 2022Visit https://bit.ly/3spcWmq for more information Next Generation CAR-TCR Summit, February 22 - 24, 2022, in Lo

Yahoo | February 10, 2022

We're Not Very Worried About IN8bio's (NASDAQ:INAB) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | January 31, 2022

IN8bio to Present at Upcoming January Investor Conferences

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present at four upcoming virtual investor conferences in January. Event:H.C. Wainwright & Co. BioConnect ConferencePresentation:On-demand virtual presentationDate:January 10-13, 202

Yahoo | January 10, 2022

Mizuho Securities Sticks to Its Buy Rating for IN8bio (INAB)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $12.00. The company's shares closed last Thursday at $4.00. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 11.5% and a 41.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics. Currently, the analyst consensus on IN8bio is a Moderate Buy with an average price target of $12.00.

Christine Brown on TipRanks | January 6, 2022

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

INB-200 is the first-ever genetically modified gamma-delta T cell therapy in clinical trials and is currently in a repeated-dose escalation cohort Cohort 1 dosing is complete with three patients who received a single dose of INB-200 with no dose limiting toxicities (DLTs), cytokine release syndrome (CRS), or neurotoxicity, and a manageable safety profile Cohort 2 is enrolling with one patient having received all three doses of INB-200, the first-ever repeat dosing of genetically modified gamma-d

Yahoo | January 6, 2022

Read More 'INAB' Stories Here

INAB Price Returns

1-mo -29.55%
3-mo -45.62%
6-mo -65.04%
1-year N/A
3-year N/A
5-year N/A
YTD -46.24%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6134 seconds.